相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
Mark A. Agius et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Bruce A. C. Cree et al.
LANCET (2019)
What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
Shahd H. M. Hamid et al.
JOURNAL OF NEUROLOGY (2017)
Neuromyelitis Spectrum Disorders
Brian G. Weinshenker et al.
MAYO CLINIC PROCEEDINGS (2017)
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations
Bruce A. C. Cree et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations
Bruce A. C. Cree et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
Ding Chen et al.
JOURNAL OF CLINICAL MEDICINE (2016)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
B lymphocytes in neuromyelitis optica
Jeffrey L. Bennett et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
Ronald Herbst et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
分享论文
